MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - pharmaceuticals
- ASTRAZENECA PHARMA - STERLING BIOTECH
ASTRAZENECA PHARMA vs STERLING BIOTECH - Comparison Results
ASTRAZENECA PHARMA Change
AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More
STERLING BIOTECH 
Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More
Current Valuations
| ASTRAZENECA PHARMA | STERLING BIOTECH | ASTRAZENECA PHARMA/ STERLING BIOTECH |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 73.6 | -0.4 | - | View Chart |
| P/BV | x | 20.7 | 0.0 | 145,569.2% | View Chart |
| Dividend Yield | % | 0.0 | 0.0 | - |
Financials
 ASTRAZENECA PHARMA  STERLING BIOTECH |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| ASTRAZENECA PHARMA Mar-18 |
STERLING BIOTECH Dec-13 |
ASTRAZENECA PHARMA/ STERLING BIOTECH |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 1,278 | 11 | 12,171.4% | |
| Low | Rs | 883 | 3 | 25,958.8% | |
| Sales per share (Unadj.) | Rs | 228.4 | 26.8 | 852.0% | |
| Earnings per share (Unadj.) | Rs | 10.4 | -15.0 | -69.3% | |
| Cash flow per share (Unadj.) | Rs | 16.3 | -5.5 | -297.7% | |
| Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
| Dividend yield (eoy) | % | 0 | 0 | - | |
| Book value per share (Unadj.) | Rs | 98.8 | 54.9 | 180.0% | |
| Shares outstanding (eoy) | m | 25.00 | 267.87 | 9.3% | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 4.7 | 0.3 | 1,824.3% | |
| Avg P/E ratio | x | 104.2 | -0.5 | -22,432.3% | |
| P/CF ratio (eoy) | x | 66.4 | -1.3 | -5,222.1% | |
| Price / Book Value ratio | x | 10.9 | 0.1 | 8,636.9% | |
| Dividend payout | % | 0 | 0 | - | |
| Avg Mkt Cap | Rs m | 27,008 | 1,862 | 1,450.7% | |
| No. of employees | `000 | 1.4 | 1.4 | 100.1% | |
| Total wages/salary | Rs m | 1,535 | 547 | 280.8% | |
| Avg. sales/employee | Rs Th | 4,210.9 | 5,303.3 | 79.4% | |
| Avg. wages/employee | Rs Th | 1,132.2 | 403.8 | 280.4% | |
| Avg. net profit/employee | Rs Th | 191.1 | -2,959.0 | -6.5% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 5,710 | 7,181 | 79.5% | |
| Other income | Rs m | 123 | 43 | 287.6% | |
| Total revenues | Rs m | 5,833 | 7,223 | 80.7% | |
| Gross profit | Rs m | 463 | 947 | 48.9% | |
| Depreciation | Rs m | 147 | 2,543 | 5.8% | |
| Interest | Rs m | 0 | 4,377 | 0.0% | |
| Profit before tax | Rs m | 438 | -5,931 | -7.4% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 179 | -1,924 | -9.3% | |
| Profit after tax | Rs m | 259 | -4,007 | -6.5% | |
| Gross profit margin | % | 8.1 | 13.2 | 61.5% | |
| Effective tax rate | % | 40.8 | 32.4 | 125.9% | |
| Net profit margin | % | 4.5 | -55.8 | -8.1% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 3,209 | 14,335 | 22.4% | |
| Current liabilities | Rs m | 2,070 | 49,809 | 4.2% | |
| Net working cap to sales | % | 20.0 | -494.0 | -4.0% | |
| Current ratio | x | 1.6 | 0.3 | 538.8% | |
| Inventory Days | Days | 72 | 403 | 17.9% | |
| Debtors Days | Days | 35 | 171 | 20.5% | |
| Net fixed assets | Rs m | 790 | 55,432 | 1.4% | |
| Share capital | Rs m | 50 | 268 | 18.7% | |
| "Free" reserves | Rs m | 2,419 | 13,935 | 17.4% | |
| Net worth | Rs m | 2,469 | 14,701 | 16.8% | |
| Long term debt | Rs m | 0 | 9,478 | 0.0% | |
| Total assets | Rs m | 4,605 | 73,988 | 6.2% | |
| Interest coverage | x | NM | -0.4 | - | |
| Debt to equity ratio | x | 0 | 0.6 | 0.0% | |
| Sales to assets ratio | x | 1.2 | 0.1 | 1,277.5% | |
| Return on assets | % | 5.6 | 0.5 | 1,123.2% | |
| Return on equity | % | 10.5 | -27.3 | -38.5% | |
| Return on capital | % | 17.7 | -6.4 | -276.0% | |
| Exports to sales | % | 0 | 25.9 | 0.0% | |
| Imports to sales | % | 0 | 0.2 | 0.0% | |
| Exports (fob) | Rs m | NA | 1,860 | 0.0% | |
| Imports (cif) | Rs m | NA | 12 | 0.0% | |
| Fx inflow | Rs m | 300 | 1,860 | 16.1% | |
| Fx outflow | Rs m | 2,015 | 25 | 8,095.3% | |
| Net fx | Rs m | -1,715 | 1,835 | -93.5% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 88 | 1,719 | 5.1% | |
| From Investments | Rs m | -94 | -3,148 | 3.0% | |
| From Financial Activity | Rs m | NA | 1,426 | 0.0% | |
| Net Cashflow | Rs m | -6 | -3 | 167.6% | |
Share Holding
| Indian Promoters | % | 0.0 | 33.9 | - | |
| Foreign collaborators | % | 75.0 | 0.0 | - | |
| Indian inst/Mut Fund | % | 0.3 | 0.0 | - | |
| FIIs | % | 15.7 | 9.9 | 158.6% | |
| ADR/GDR | % | 0.0 | 16.9 | - | |
| Free float | % | 9.1 | 39.3 | 23.2% | |
| Shareholders | 12,856 | 21,482 | 59.8% | ||
| Pledged promoter(s) holding | % | 0.0 | 55.9 | - |
Compare ASTRAZENECA PHARMA With: JUBILANT LIFE SCIENCES DR. DATSONS LABS CADILA HEALTHCARE NOVARTIS PANACEA BIOTECH
Compare ASTRAZENECA PHARMA With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)
What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!
Related Views on News
ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)
Aug 8, 2019 | Updated on Aug 8, 2019For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)
May 27, 2019 | Updated on May 27, 2019For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)
Mar 29, 2019 | Updated on Mar 29, 2019Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.
ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)
Feb 12, 2019 | Updated on Feb 12, 2019For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
ASTRAZENECA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 66.7% (Quarterly Result Update)
Nov 27, 2018 | Updated on Nov 27, 2018For the quarter ended September 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 91 m (down 66.7% YoY). Sales on the other hand came in at Rs 2 bn (down 1.8% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
More Views on NewsMost Popular
Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)
Sep 12, 2019News headlines predict gloom and doom for India these days. You should ignore them.
A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)
Sep 16, 2019The stock market today is throwing up a great opportunity to pile on quality stocks.
A Recession Proof Stock You Can Bet On(Profit Hunter)
Sep 10, 2019Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.
My 7 Stocks to Buy Are Companies Which Will Be a Big Part of New India(The 5 Minute Wrapup)
Sep 19, 2019The India we knew is changing. Here's how you can benefit from this change.
The 5 Best Trading Opportunities I've Spotted(Profit Hunter)
Sep 13, 2019These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.
MoreASTRAZENECA PHARMA SHARE PRICE
Sep 20, 2019 (Close)
TRACK ASTRAZENECA PHARMA
- Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON ASTRAZENECA PHARMA
ASTRAZENECA PHARMA 5-YR ANALYSIS
COMPARE ASTRAZENECA PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.